Biosimilars in Brazil: Intellectual Property, Regulatory and Market Landscape
They include, among others, monoclonal antibodies, recombinant proteins, vaccines, hormones, blood-derived products and advanced cell-based therapies.
Useful takeaways from this story.
They include, among others, monoclonal antibodies, recombinant proteins, vaccines, hormones, blood-derived products and advanced cell-based therapies.
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
They include, among others, monoclonal antibodies, recombinant proteins, vaccines, hormones, blood-derived products and advanced cell-based therapies.
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.